Iran-Made EGF Drug Treats Diabetic Foot Ulcers, Burns
“For the first time in Iran, we have succeeded in producing epidermal growth factor medicine. This drug is used in the treatment of diabetic foot ulcers and 3rd and 4th grade burns,” Fahimeh Mohammad Hosseini, the managing director of the knowledge-based company.
Noting that the primary component of this product is epidermal growth factor, she said, “This growth factor is basically used for wound healing and epidermal cell proliferation.”
“Epidermis is a factor that the body needs to repair all wounds, of course this growth factor is naturally present in the body, but when the body is wounded, the pH of the wounded area changes and the production of the epidermis decreases; therefore, if we add this growth factor to it externally, wound healing will be done faster,” Mohammad Hosseini said.
“Our manufactured drug can be produced in two injectable and topical forms, and we have industrialized the topical type,” she added.
Epidermal growth factor (EGF) is a single polypeptide of 53 amino acid residues which is involved in the regulation of cell proliferation.
EGF exerts its effects in the target cells by binding to the plasma membrane located EGF receptor. The EGF receptor is a transmembrane protein tyrosine kinase.
4155/v
